Bestmade Natural Products Lithium Chloride (lith Mur)

Dosage for Lithium must be highly individualized based on the patient's clinical response and serum Lithium levels. There is no 'one size fits all' dose.

• Acute Manic Episodes: Healthcare providers typically initiate therapy with 600 mg to 900 mg per day in divided doses. This may be rapidly titrated upward to 1,200 mg to 1,800 mg per day to achieve a therapeutic serum level between 1.0 and 1.5 mEq/L.
• Maintenance Therapy: Once the acute episode is stabilized, the dose is usually reduced. The target maintenance serum level is generally 0.6 to 1.2 mEq/L. Typical daily dosages range from 900 mg to 1,200 mg, divided into two or three doses.

Lithium is generally not recommended for children under the age of 12 for the treatment of bipolar disorder, as safety and efficacy have not been established in this population. For adolescents aged 12 to 18, dosing is similar to adult titration but requires even more frequent monitoring of renal and thyroid function due to the potential impact on growth and development. Healthcare providers will calculate doses based on weight and serum level targets.

Renal Impairment

Since Lithium is excreted almost exclusively by the kidneys, any degree of renal impairment requires significant dose reductions. In patients with a Creatinine Clearance (CrCl) between 10-50 mL/min, the dose may be reduced by 25-50%. If CrCl is less than 10 mL/min, Lithium is generally avoided or used with extreme caution and daily monitoring.

Hepatic Impairment

Because Lithium is not metabolized by the liver, no specific dose adjustments are required for patients with liver disease. However, these patients must still be monitored for fluid balance and electrolyte stability.

Elderly Patients

Older adults often have reduced renal clearance and a smaller volume of distribution. Healthcare providers typically start with very low doses (e.g., 150-300 mg daily) and titrate slowly. Target serum levels in the elderly may be lower (0.4 to 0.8 mEq/L) to minimize the risk of neurotoxicity and falls.

• Consistency is Key: Take Lithium exactly as prescribed, at the same time(s) each day. Do not skip doses or stop taking the medication without consulting your doctor.
• With Food: To minimize stomach upset, it is often recommended to take Lithium with a meal or a glass of milk.
• Hydration and Salt: Maintain a consistent intake of fluids (8-12 glasses of water a day) and salt. Sudden changes in sodium intake (e.g., starting a low-salt diet) can cause Lithium levels to rise to dangerous levels.
• Swallow Whole: If you are taking extended-release tablets, do not crush, chew, or break them, as this can cause the entire dose to be released at once, increasing the risk of toxicity.
• Storage: Store at room temperature (68°F to 77°F), away from moisture and heat.

If you miss a dose, take it as soon as you remember. However, if it is within a few hours of your next scheduled dose, skip the missed dose and return to your regular schedule. Never double the dose to make up for a missed one, as this can lead to acute toxicity.

Lithium toxicity is a medical emergency. Signs of an overdose include severe nausea, vomiting, diarrhea, extreme drowsiness, muscle weakness, lack of coordination (ataxia), blurred vision, and ringing in the ears (tinnitus). In severe cases, it can lead to seizures, coma, and kidney failure. If an overdose is suspected, call 911 or your local emergency services immediately. Treatment often requires gastric lavage and, in severe cases, hemodialysis to rapidly remove Lithium from the blood.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose without medical guidance. Regular blood tests are the only way to ensure your dose is safe.

Many patients experience mild side effects when starting Lithium or when the dose is increased. These often diminish over time as the body adjusts:

• Increased Thirst (Polydipsia): Patients may feel a constant need to drink water.
• Frequent Urination (Polyuria): Due to the kidneys' handling of Lithium and increased fluid intake.
• Fine Hand Tremor: A slight shakiness in the hands, often most noticeable when performing fine motor tasks. This can sometimes be managed with beta-blockers if it interferes with daily life.
• Mild Nausea: Especially during the first few weeks of therapy.
• Weight Gain: This is a common long-term side effect, often related to metabolic changes or increased consumption of high-calorie beverages to quench thirst.

• Diarrhea and Vomiting: Persistent gastrointestinal distress should be reported to a doctor, as it can lead to dehydration and toxicity.
• Dermatological Issues: Acne or psoriasis may worsen or appear for the first time.
• Muscle Weakness: A feeling of 'heaviness' in the limbs.
• Cognitive 'Fog': Some patients report feeling mentally slowed or having difficulty concentrating.

• Hair Thinning: Usually reversible upon discontinuation or dose reduction.
• Leukocytosis: A benign increase in white blood cell counts.
• Brugada Syndrome Unmasking: Rare heart rhythm abnormalities in susceptible individuals.

> Warning: Stop taking Lithium and call your doctor immediately if you experience any of these symptoms, as they may indicate toxicity or a severe adverse reaction:

• Signs of Toxicity: Coarse tremors (large, jerky movements), severe ataxia (loss of balance), slurred speech, and significant confusion.
• Serotonin Syndrome: If taken with other serotonergic drugs, symptoms like high fever, agitation, increased reflexes, and sweating may occur.
• Kidney Dysfunction: Significant changes in how much you urinate or swelling in the legs and ankles.
• Severe Allergic Reaction: Hives, difficulty breathing, or swelling of the face, lips, and throat.
• Vision Changes: Blurred vision or seeing double.

• Hypothyroidism: Lithium can interfere with the thyroid's ability to produce hormones. Patients may experience fatigue, weight gain, and cold intolerance. This is usually managed by adding thyroid hormone replacement therapy rather than stopping Lithium.
• Nephrogenic Diabetes Insipidus (NDI): Long-term use can reduce the kidneys' ability to concentrate urine, leading to chronic polyuria.
• Chronic Kidney Disease: In a small percentage of patients, long-term Lithium use (usually over decades) can lead to interstitial nephritis and a slow decline in glomerular filtration rate (GFR).
• Hyperparathyroidism: Lithium can cause elevated calcium levels by affecting the parathyroid glands.

Lithium carries a significant FDA-mandated warning regarding Lithium Toxicity. The warning states that Lithium toxicity is closely related to serum Lithium levels and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum Lithium determinations should be available before initiating therapy. Toxicity can occur even at therapeutic levels if the patient becomes dehydrated or has altered sodium levels. Healthcare providers must educate patients on the early signs of toxicity and the importance of regular blood monitoring.

Report any unusual symptoms to your healthcare provider immediately. Your doctor may adjust your dose or order blood tests to ensure your safety.

Lithium is a highly effective but complex medication that requires active participation from the patient in their own care. The most critical safety point is the maintenance of stable Lithium blood levels. Small changes in diet, hydration, or other medications can cause these levels to fluctuate dangerously. Patients must be aware that Lithium has a narrow therapeutic window, meaning the difference between a helpful dose and a harmful one is very small.

Warning: Lithium Toxicity. Lithium toxicity is a serious condition that can lead to permanent neurological damage or death. It is directly related to the concentration of Lithium in the blood. Because the therapeutic range is so narrow, patients must undergo regular blood testing. Toxicity can occur at levels only slightly above the therapeutic range. Risk factors for toxicity include dehydration, diarrhea, vomiting, excessive sweating, and the use of certain other medications like diuretics or NSAIDs. Patients must be instructed to discontinue Lithium and contact their physician at the first sign of Lithium toxicity, such as diarrhea, vomiting, tremor, mild ataxia, lack of coordination, drowsiness, or muscular weakness.

• Dehydration Risk: Anything that causes a loss of body fluids—such as high fever, heavy exercise, or hot weather—can increase the risk of Lithium toxicity. Patients should be advised to drink plenty of fluids and maintain a steady salt intake.
• Renal Function: Lithium is cleared by the kidneys. Patients with pre-existing kidney disease must be monitored with extreme caution. Long-term use may also lead to a gradual decline in kidney function.
• Thyroid Function: Lithium can cause goiter (enlarged thyroid) and hypothyroidism. Thyroid-stimulating hormone (TSH) levels should be checked before starting treatment and every 6-12 months thereafter.
• Cardiovascular Risk: Lithium can cause EKG changes (such as T-wave flattening) and may unmask underlying heart conditions like Brugada Syndrome. Patients with a history of heart disease should have an EKG before starting Lithium.
• Suicidality: While Lithium is known to reduce suicide risk long-term, all patients with bipolar disorder should be monitored for worsening depression or suicidal thoughts, especially during the early stages of treatment.

To ensure safety, the following tests are typically required:

• Serum Lithium Levels: Initially every few days until stable, then every 1-3 months.
• Renal Function (BUN and Creatinine): Every 3-6 months.
• Thyroid Function (TSH): Every 6-12 months.
• Electrolytes: Specifically sodium and calcium levels.
• Complete Blood Count (CBC): Periodically, as Lithium can cause a benign increase in white blood cell counts.

Lithium can cause drowsiness, dizziness, or blurred vision, especially when first starting the medication or during dose adjustments. Do not drive or operate heavy machinery until you know how Lithium affects you.

Alcohol should be avoided or strictly limited while taking Lithium. Alcohol can increase the sedative effects of the medication and, more importantly, can cause dehydration, which significantly increases the risk of Lithium toxicity.

Do not stop taking Lithium suddenly. Abrupt discontinuation can lead to a rapid relapse of manic or depressive symptoms. If the medication needs to be stopped, your healthcare provider will provide a tapering schedule to slowly reduce the dose over several weeks or months.

> Important: Discuss all your medical conditions, including any history of kidney, heart, or thyroid problems, with your healthcare provider before starting Lithium.

Certain medications should never be used with Lithium due to the extreme risk of toxicity or severe adverse events:

• Specific Diuretics (e.g., Thiazides): Diuretics like hydrochlorothiazide cause the kidneys to excrete sodium while retaining Lithium, rapidly leading to toxic levels. If a diuretic is absolutely necessary, the Lithium dose must be reduced by 50% and monitored daily.
• ACE Inhibitors (e.g., Lisinopril, Enalapril): These blood pressure medications can significantly reduce the renal clearance of Lithium, causing levels to spike unexpectedly.
• Angiotensin II Receptor Blockers (ARBs): Similar to ACE inhibitors, drugs like losartan can increase Lithium concentrations to dangerous levels.

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Common over-the-counter drugs like ibuprofen (Advil/Motrin) and naproxen (Aleve) can increase Lithium levels by reducing renal blood flow. Aspirin and sulindac are generally considered safer alternatives, but consultation with a doctor is required.
• Serotonergic Drugs (SSRIs, SNRIs, Triptans): Combining Lithium with antidepressants like fluoxetine or sertraline increases the risk of Serotonin Syndrome, a potentially life-threatening condition.
• Calcium Channel Blockers (e.g., Verapamil, Diltiazem): These may increase the risk of neurotoxicity (confusion, tremors) even if Lithium blood levels remain within the normal range.
• Antipsychotics (e.g., Haloperidol): In rare cases, the combination of Lithium and high-dose antipsychotics has been linked to an encephalopathic syndrome (weakness, fever, tremors, confusion).

• Caffeine: High intake of caffeine (coffee, tea, soda) can increase the renal clearance of Lithium, potentially lowering its effectiveness. Conversely, suddenly stopping caffeine can cause Lithium levels to rise.
• Sodium Bicarbonate: Found in some antacids, this can increase the excretion of Lithium, making it less effective.
• Theophylline: Used for asthma, this medication can lower Lithium levels significantly.

• Sodium (Salt): This is the most critical dietary interaction. Lithium and sodium are handled similarly by the kidneys. If you suddenly decrease your salt intake, your kidneys will retain more Lithium, leading to toxicity. If you suddenly increase salt, Lithium levels may drop, making the drug less effective. Maintain a consistent, moderate salt intake.
• Hydration: Dehydration from any cause (low fluid intake, excessive sweating) will cause Lithium levels to rise.

• St. John's Wort: May increase the risk of serotonin syndrome.
• Psyllium (Fiber Supplements): May interfere with the absorption of Lithium if taken at the same time.
• Diuretic Herbs: Herbs like dandelion or juniper may act as natural diuretics and increase Lithium levels.

Lithium can cause a benign (non-harmful) increase in the white blood cell count (WBC), which may be mistaken for an infection on a standard blood test. It can also affect tests for parathyroid hormone and blood glucose. Always inform laboratory personnel that you are taking Lithium.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even 'natural' products can have dangerous interactions with Lithium.

Lithium must NEVER be used in the following circumstances due to the extreme risk of life-threatening complications:

• Severe Renal Disease: Since the kidneys are the only way the body removes Lithium, severe impairment (Stage 4 or 5 Chronic Kidney Disease) will lead to rapid and fatal toxicity.
• Severe Cardiovascular Disease: Lithium can interfere with cardiac conduction and may cause fatal arrhythmias in patients with significant heart damage or unstable heart disease.
• Severe Dehydration or Sodium Depletion: Patients who are severely dehydrated or on a salt-restricted diet are at immediate risk for Lithium toxicity.
• Known Hypersensitivity: While rare, any patient with a documented allergy to Lithium salts or any component of the formulation must not take the drug.

In these cases, a healthcare provider will perform a careful risk-benefit analysis:

• Mild to Moderate Renal Impairment: Requires lower doses and very frequent monitoring.
• Thyroid Disease: Pre-existing hypothyroidism must be treated and stabilized before starting Lithium.
• Pregnancy (First Trimester): Lithium is associated with a specific heart defect in the fetus (Ebstein's Anomaly). However, if the mother's bipolar disorder is severe, the doctor may decide the benefit outweighs the risk.
• Epilepsy: Lithium may lower the seizure threshold in some patients, although it was historically used as an anticonvulsant.
• Parkinson's Disease: Lithium can worsen tremors and motor symptoms.

There is no known cross-sensitivity between Lithium and other major drug classes. However, patients sensitive to bromide (in the case of Lithium Bromide) or specific dyes and fillers in the tablets (like tartrazine) should exercise caution and check the specific inactive ingredients of the brand they are prescribed.

> Important: Your healthcare provider will evaluate your complete medical history, including your kidney function and heart health, before prescribing Lithium.

Lithium is classified as FDA Pregnancy Category D. This means there is evidence of human fetal risk, but the benefits may outweigh the risks in certain life-threatening situations. The primary concern is Ebstein's Anomaly, a rare heart valve defect that occurs more frequently in infants exposed to Lithium during the first trimester (the risk is approximately 1 in 1,000 to 2,000, compared to 1 in 20,000 in the general population). If Lithium is used during pregnancy, levels must be monitored extremely closely, as the mother's kidney function changes significantly throughout gestation. Doses often need to be increased during pregnancy and then rapidly decreased immediately after delivery to avoid toxicity.

Lithium is excreted into breast milk, and concentrations in the infant's blood can reach 30% to 50% of the mother's levels. This can lead to 'floppy infant syndrome,' characterized by lethargy, cyanosis (blue skin), and poor muscle tone. Most healthcare providers recommend against breastfeeding while taking Lithium. If a mother chooses to breastfeed, the infant must be monitored closely for Lithium levels and thyroid function.

Lithium is not FDA-approved for children under 12. In adolescents (12-18), it is used for Bipolar I Disorder. Pediatric patients are more sensitive to the effects of Lithium on the thyroid and kidneys. Long-term studies on the impact of Lithium on bone growth and development are limited, so it is reserved for severe cases where other treatments have failed.

Elderly patients (over 65) are at a much higher risk for Lithium-induced neurotoxicity and kidney injury. Age-related declines in glomerular filtration rate (GFR) mean that Lithium stays in the body longer. Older adults are also more likely to be taking interacting medications like ACE inhibitors or diuretics. Healthcare providers use a 'start low, go slow' approach, often targeting lower serum levels (0.4-0.8 mEq/L) to maintain safety.

Lithium is contraindicated in severe renal failure. For mild to moderate impairment, the dose is typically reduced by 25% to 50%. Patients on hemodialysis can take Lithium, but it must be administered after the dialysis session, as the procedure rapidly removes the drug from the blood.

No dose adjustment is typically needed for patients with liver disease, as Lithium is not metabolized by the liver. However, these patients should be monitored for fluid shifts (like ascites) which can affect the volume of distribution of the drug.

> Important: Special populations require individualized medical assessment and more frequent monitoring to ensure the safe use of Lithium.

Lithium's molecular mechanism is complex. It acts as a substitute for other monovalent and divalent cations. Its primary action is the inhibition of Inositol Monophosphatase (IMPase). By blocking this enzyme, Lithium depletes the supply of free inositol, which is necessary for the synthesis of phosphatidylinositol-4,5-bisphosphate (PIP2). This effectively 'turns down the volume' on overactive G-protein coupled receptor signaling pathways (the phosphoinositide cycle) that are linked to manic states. Furthermore, Lithium inhibits Glycogen Synthase Kinase-3 beta (GSK-3β), which has downstream effects on gene transcription and neuroprotection, potentially increasing levels of Brain-Derived Neurotrophic Factor (BDNF).

Lithium does not produce a sedative or stimulant effect in healthy individuals. In patients with mania, it produces a stabilizing effect over 5 to 10 days. It has a high degree of specificity for mood disorders. There is no evidence of physiological addiction or tolerance development, although the body's handling of the drug can change over years of use.

| Parameter | Value |

|---|---|

| Bioavailability | 95% - 100% |

| Protein Binding | 0% |

| Half-life | 18 - 36 hours (Adults); up to 48+ hours (Elderly) |

| Tmax | 1 - 3 hours (IR); 4 - 12 hours (ER) |

| Metabolism | None (Not metabolized) |

| Excretion | Renal (95%+) |

• Molecular Formula: LiBr (for Lithium Bromide); Li2CO3 (for Lithium Carbonate)
• Molecular Weight: 86.85 g/mol (Bromide); 73.89 g/mol (Carbonate)
• Solubility: Highly soluble in water.
• Description: Lithium is the lightest solid element and an alkali metal. In pharmaceutical form, it is a white, odorless crystalline powder.

Lithium is the primary member of the Antimanic Agents or Mood Stabilizers class. While it shares some therapeutic goals with anticonvulsants (like valproate) and atypical antipsychotics (like quetiapine), its chemical structure and mechanism as a simple cation are unique in pharmacology.